http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
진행성 대장암에 대한 5-Fluorouracil 및 Low Dose Leucovorin 복합화학 요법
안명주 ( An Myeong Ju ),서철원 ( Seo Cheol Won ),이규형 ( Lee Gyu Hyeong ),이정신 ( Lee Jeong Sin ),김상희 ( Kim Sang Hui ),김진천 ( Kim Jin Cheon ),박건춘 ( Park Geon Chun ) 대한내과학회 1992 대한내과학회지 Vol.42 No.6
Background A total of 29 patients with metastatic or recurrent colorectal carcinoma were studied to evaluate the effectiveness and toxicity of low dose leucovorin modulated 5-fluorouracil (5-FU). Methods: All patients were treated with low dose leucovorin, 20 ㎎/㎡ Ⅳ bolus on Days 1-5 and 5-fluorouracil, 400 ㎎/㎡ Ⅳ bolus on Days 1-5, every 4 weeks. Results: Of the 27 patients evaluable for response, 2(7%) had complete response and 6(22%) had partial response with the objective response rate of 29%. The median duration of response was 17 weeks and the median survival of all patients was 30 weeks. In the analysis of the response according to various characteristics of the patients, there was no significant difference (p> 0.05). Toxicity was mainly gastrointestinal, especially diarrhea and mucositis, but the grade was low. Hematologic toxicity was also mild. Conclusion: This study indicates that this regimen of low dose leucovorin plus 5-FU has mild toxicity, moderate response rate and good compliance for patients with recurrent and metastatic colorectal cancer.
진행성 비소세포 폐암에 대한 Mitomycin C, Vinblastine 및 Cisplatin(MVP) 3제 복합 화학요법의 치료 효과
김상위 ( Kim Sang Wi ),안명주 ( An Myeong Ju ),서철원 ( Seo Cheol Won ),이규형 ( Lee Gyu Hyeong ),이정신 ( Lee Jeong Sin ),고윤석 ( Go Yun Seog ),김우성 ( Kim U Seong ),김원동 ( Kim Won Dong ),김상희 ( Kim Sang Hui ) 대한내과학회 1993 대한내과학회지 Vol.44 No.2
Background : Advanced non-small cell lung cancer (NSCLC) is still a lethal disease and one of the most important causes of cancer-related death. Role of systemic chemotherapy seems to be pallicative and showed objective response of 30-40%. We treated 33 patients with advanced NSCLC with combination therapy of mitomycin C, vinblastine, and cisplatin (MVP) to evaluate the clinical activity and side effect of this combination. Mothods : Cisplatin was infused intravenously on day l at the dose of 60mg/㎡ with pre-and post-hydration and mitomycin C 6mg/㎡ (maximum 10mg) and vinblastine 6mg/㎡ (maximum 8mg) were given intravenously on day 2. The treatiment was repeated every 3-4 weeks, and at least 2 cycles of chemotherapy were administered. Results : Nine patients (27%) had partial responses and no one had complete response. Median response duration was 16 weeks, reange (4+to 28 weeks). The toxicity included mild and transient nausea/vomiting, mild to moderate leukopenia, and mild peripheral neuropathy, All of them were well tolerated and recovered fully before the next cycle of chemotherapy. Conelusion : MVP combination chemotherapy is moderately active against advanced NSCLC and relatively well tolerated.